Chronic kidney disease (CKD) is associated with excess cardiovascular mortality, resulting
from both traditional and nontraditional, CKD-specific, cardiovascular risk factors …

KDIGO guidelines recommend dietary phosphate restriction to lower serum phosphate
levels in CKD stages 3–5. Recent studies suggest that dietary phosphate intake is only …

This chapter talks about pathophysiology of chronic kidney disease mineral bone disorder
(CKD‐MBD). It discusses the pathogenetic factors such as fibroblast growth factor 23 …

Background Benefits of phosphate-lowering interventions on clinical outcomes in patients
with CKD are unclear; systematic reviews have predominantly involved patients on dialysis …

Background: Previous trials of binders in chronic kidney disease (CKD) stages 3–5 have
shown only modest changes in serum phosphate but evaluated morning phosphate. It is …

Phosphorus is an essential micromineral with a key role in cellular metabolism and tissue
structure. Serum phosphorus is maintained in a homeostatic range by the intestines, bones …

Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems, and
their prevalence rates have increased with the aging of the population. They are associated …

Chronic kidney disease–mineral and bone disorder (CKD-MBD) is characterized by bone
abnormalities, vascular calcification, and an array of laboratory abnormalities. The latter …

Phosphate binders are among the most common medications prescribed to patients with
kidney failure receiving dialysis and are often used in advanced chronic kidney disease …

The emergence of fibroblast growth factor 23 as a potentially modifiable risk factor in CKD
has led to growing interest in its measurement as a tool to assess patient risk and target …